Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Axiom Research

Neither a doctor nor a teaching hospital

Research payments

$168,902

32 payments

Through program year 2025, Axiom Research is reported as receiving $168,902 in research payments, across 32 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $31,852 3
2024 Research $17,740 3
2023 Research $1,661 1
2022 Research $37,302 6
2021 Research $57,562 5
2020 Research $15,075 2
2019 Research $7,710 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $55,429 3 payments
  2. AbbVie, Inc. $44,649 8 payments
  3. Pfizer Inc. $31,852 3 payments
  4. Allergan Inc. $23,317 15 payments
  5. Amgen Inc. $13,655 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $55,429 3 payments
  2. An Interventional Efficacy and Safety Phase 3 Doubleblind Parallel Group Study to Investigate Intermittent Prevention of Menstrual Migraine With Rimegepant Compared With Placebo in Women Participants 18 to 45 Years of Age $31,852 3 payments
  3. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $19,143 6 payments
  4. Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. $16,909 3 payments
  5. M23-894 ABBV-932 Ph 2 BPD $16,890 1 payment
  6. Medication Overuse Headache Study (MOH)_ $13,655 3 payments
  7. A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine $10,000 2 payments
  8. Efficacy and Safety of Bimatoprost Sustained-Release Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension $3,642 8 payments
  9. M23-714 Ubrelvy Menstrual Migraine $850 2 payments
  10. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $532 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record